title: The intervention effect of zinc supplementation on irbesartan treatment for atherosclerosis of ApoE-/- mice.
abstract: To explore the influence of zinc supplementation on irbesartan treatment for atherosclerosis of ApoE gene-deleted mice. Atherosclerosis model mice induced by normal feed were randomly divided into ApoE-/-control group, irbesartan group and zinc sulfate+ irbesartan group, 6 mice each group; C57BL/6J mice with normal feed were regarded as blank control group (n=6). Blank control group and ApoE-/- control group were not given any medical treatment, and irbesartan group were treated with irbesartan (50mg/kg/d), and zinc sulfate+irbesartan group were given zinc sulfate (25mmol/L) treatment besides the administration of irbesartan group. The blood pressure of each mouse was recorded and the blood lipid level was detected after 15 weeks' treatment. The internal inflammatory reaction of the mice was evaluated according to IL-6 and TNF-α level. The oxidative stress was evaluated according to MDA and SOD levels. And the atherosclerosis plaque was analyzed with immunohistochemistry. After 15 weeks of drug administration, it showed that the total cholesterol level, LDL-C, HDL-C and blood pressure level (P<0.05) of the mice were improved significantly with the administration of zinc sulfate+irbesartan compared with irbesartan group, and the oxidative stress response and inflammatory reaction of mice in zinc sulfate+irbesartan group decreased more significantly than those of irbesartan group (P<0.05). In the detection of atherosclerosis plaque, the ratio of plaque area and tube area as well as the improvement degree of mean aortic IMT in zinc sulfate+irbesartan group were superior to those of irbesartan group (P<0.05). Zinc supplementation has certain therapeutic effect on the advanced atherosclerosis of ApoE gene-deleted mice, which can significantly improve the efficacy of irbesartan.
authors.affiliation: Henan Infection Disease Hospital, No.29, South Jingguang Rd., Zhengzhou Henan Province, China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Li
authors.affiliation: Henan Infection Disease Hospital, No.29, South Jingguang Rd., Zhengzhou Henan Province, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Wang
authors.affiliation: People's Hospital of Zhengzhou, No.33, Huanghe Rd., Zhengzhou Henan Province, China.
authors.forename: Guofang
authors.initials: G
authors.lastname: Xu
authors.affiliation: People's Hospital of Zhengzhou, No.33, Huanghe Rd., Zhengzhou Henan Province, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Ji
authors.affiliation: Henan Infection Disease Hospital, No.29, South Jingguang Rd., Zhengzhou Henan Province, China.
authors.forename: Chuan
authors.initials: C
authors.lastname: Qin
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology; D001011:Aorta / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D001018:Aortic Diseases / Q000097:blood / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D001057:Apolipoproteins E / Q000172:deficiency* / Q000235:genetics; D050197:Atherosclerosis / Q000097:blood / Q000235:genetics / Q000503:physiopathology / Q000517:prevention & control*; D015415:Biomarkers / Q000097:blood; D001713:Biphenyl Compounds / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D016207:Cytokines / Q000097:blood; D019587:Dietary Supplements; D004195:Disease Models, Animal; D020022:Genetic Predisposition to Disease; D018836:Inflammation Mediators / Q000097:blood; D000077405:Irbesartan; D008055:Lipids / Q000097:blood; D008297:Male; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D018384:Oxidative Stress / Q000187:drug effects; D010641:Phenotype; D058226:Plaque, Atherosclerotic; D013777:Tetrazoles / Q000494:pharmacology*; D013997:Time Factors; D019287:Zinc Sulfate / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D001057:Apolipoproteins E; D015415:Biomarkers; D001713:Biphenyl Compounds; D016207:Cytokines; D018836:Inflammation Mediators; D008055:Lipids; D013777:Tetrazoles; D019287:Zinc Sulfate; D000077405:Irbesartan